09:48 AM EDT, 03/12/2026 (MT Newswires) -- Sellas Life Sciences ( SLS ) said Thursday that the first patient has been enrolled in its phase 2 trial evaluating SLS009, or tambiciclib, in newly diagnosed, first-line acute myeloid leukemia patients.

The study will enroll about 80 patients and will have two groups, one for newly diagnosed patients unlikely to benefit from the standard Venetoclax/Azacitide therapy and another for patients who initiate treatment with the standard therapy but demonstrate a confirmed lack of any response after two treatment cycles, the company said.

Sellas said it expects to report topline data in Q4.

Price: 5.49, Change: +0.01, Percent Change: +0.11